PRSS3 and gastric cancer: Several articles have reported an increased expression of PRSS3 (mesotrypsin) in various human digestive pathologies, including colon adenocarcinoma (Zhang et al., 2021), gastric cancer (Wang et al., 2019), irritable bowel syndrome (Rolland-Fourcade et al., 2017), or pancreatitis (Szmola et al., 2003; Toldi et al., 2020).